Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Once opened, compounded semaglutide typically lasts 28 days in the fridge. Compounded semaglutide, which contains the same active ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Rybelsus (semaglutide) is a brand-name oral tablet prescribed for type 2 diabetes. As with other drugs, Rybelsus can cause side effects, such as nausea, vomiting, and constipation. Read on to ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

Ophthalmic complications were observed in patients using semaglutide and tirzepatide, but a causal link was not established. The study included nine patients, with conditions like nonarteritic ...

Let's take a closer look at each of these medications. Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s diabetes-cum-weight loss drug Ozempic for patients with both chronic kidney disease and diabetes. This came after clinical trials ...